期刊文献+

阿德福韦二吡呋酯在猕猴体内的药代动力学及在大鼠体内的组织分布 被引量:4

Pharmacokinetics of adefovir dipivoxil in monkeys and its distribution in rat tissues
暂未订购
导出
摘要 目的 研究了新型抗病毒药物阿德福韦二吡呋酯 (ADV)po给药后在动物体内的吸收、分布、代谢和消除过程。方法 采用液相色谱质谱联用方法测定样品中的药物浓度。结果 猕猴po或iv给药ADV后 ,血液中只检测到活性代谢物阿德福韦(ADF) ,因此用ADF的血药浓度 时间曲线来估算药代动力学参数。猕猴poADV后 ,tmax为 0 .99~ 1.70h ,t1/ 2 为 1.6 4~ 5 .4 3h ,Cl为 9.14~ 13.91L·h- 1·kg- 1,绝对生物利用度为 19.9%。连续 7dpo给药(每日 1次 )后未发现药物累积现象。肾脏和肝脏中ADF的含量仅次于胃肠内容物。ADF主要经肾脏排出体外。结论 在给药量范围内表现为线性动力学 ,在靶器官肝脏中分布较多 ,主要从尿液中排出。 AIM To reveal the process of absorption, distribution, metabolism and elimination of the antivirus agent adefovir dipivoxil (ADV) by animal body. METHODS Analyzing the concentration of adefovir(ADF) with LC/MS/MS method. RESULTS ADV transformed into ADF completely in plasma after po and iv administration of ADV to monkeys, so pharmacokinetic parameters were evaluated with the concentration time curves of ADF. The pharmacokinetic courses of ADF was independent of doses. After single dose po administration of ADV to monkeys, t max ranged from 0.99 h to 1.70 h, t 1/2 from 1.64 h to 5.43 h, Cl from 9.14 L·h -1 ·kg -1 to 13.91 L·h -1 ·kg -1 , absolute bioavailability was 19.9% . After multi dose (7 d, once everyday) po administration of ADV to monkeys, no drug cumulation was observed. ADF concentrations in liver and kidney were higher than other tissues besides stomach and intestine. Most of the metabolite of ADV was excreted from urine. CONCLUSION In dosage range studied pharmacokinetic behavior appeared as linear kinetic. The concentration of ADF was higher than most other tissues in liver, the target organ. ADF was excreted out of body mainly from urine.
出处 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2003年第6期447-450,共4页 Chinese Journal of Pharmacology and Toxicology
基金 国家自然科学基金资助项目 (39930 180 )~~
关键词 阿德福韦二吡呋酯 药代动力学 阿德福韦 adefovir dipivoxil pharmacokinetics adefovir
  • 相关文献

参考文献7

  • 1[1]Bronson JJ, Ho HT, De Boeck H, Woods K, Ghazzouli L, Martin JC, et al. Biochemical pharmacology of acyclic nucleotide analogues[J]. Ann NY Acad Sci, 1990, 616:398-407.
  • 2[2]Safrin S. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS[J]. J Acquir Immune Defic Syndr, 1992, 5(Suppl 1):S29-S32.
  • 3[3]Naesens L, Balzarini J, De Clercq E. Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine[J]. Drug Metab Dispos, 1992, 20(5):745-752.
  • 4[4]Shaw JP, Louie MS, Krishnamurthy VV, Arimilli MN, Jones RJ, Bidgood AM, et al. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats[J]. Drug Metab Dispos, 1997, 25(3):362-366.
  • 5[5]Yves B, Bochet M, Thibault V, Calvez V, Fievet MH, Sullivan M. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients[J]. J Hepatol, 2002, 36(Suppl 1):S138.
  • 6[6]Cundy KC, Fishback JA, Shaw JP, Lee ML, Soike KF, Visor GC, et al. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys[J]. Pharm Res, 1994, 11(6):839-843.
  • 7[7]Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients[J]. Antimicrob Agents Chemother, 1995, 39(11):2401-2405.

同被引文献26

  • 1TARRAH W, MARLON H, EVANS B, et al. Adefovir dipivoxil: a new agent for active hepatitis b virus infection[J]. Drug Forecast, 2003, 28( 1 ) : 31-34.
  • 2BENHAMOU Y, BOCHET M, CALVEZ V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study[J]. Lancet, 2001,358(9): 718-723.
  • 3KENNETH C, PATRICIA BC, ROBERTE W, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients[J]. Antimicrob Agent Chemother, 1995, 39 ( 11 ) : 2401-2405.
  • 4ROLF WS, ADENES V, RICHARD MW, et ol. Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde[J]. J Chromatogr B, 1999, 736 (1-2) : 115- 121.
  • 5XIAO YC, DAN L, LIN Z, et al. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of adefovir in human plasma [J]. Rapid Commun Mass Spectrom, 2005, 19 ( 13 ) : 1893-1898.
  • 6Cundy KC.Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir[J].Clin Pharmacokinet,1999,36 (2):127.
  • 7Hughes WT,Shenep JL,Rodman JH,et al.Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1.The pediatrics AIDS clinical trials group[J].Antimicrob Agents Chemother,2000,44(4):1041.
  • 8Keamey BP,Ramanathan S,Cheng AK,et al.Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration[J].J Clin Pharmacol,2005,45(8):935.
  • 9Ray AS,Vela JE,Olson L,Fridland A.Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells[J].Biochem Pharmacol,2004,68(9):1825-1831.
  • 10Naesens L,Balzarini J,De Clercq E.Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl) adenine[J].Drug Metab Dispos,1992,20(5):747-752.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部